Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Lucigen Continues Development of POC Platform, C Diff Test

Lucigen Continues Development of POC Platform, C Diff Test

Aug 19, 2015
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – Lucigen is continuing to develop a point-of-care molecular diagnostic platform with an initial assay designed for Clostridium difficile detection. The firm described the platform and preliminary results of trials using a prototype yesterday at Cambridge Healthtech Institute's Next Generation Dx Summit in Washington, DC.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mix of Human and Monkey

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

Fetal Tissue Policy Changes Expected

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Sequencing the Zoo

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Science Papers on Approach to Isolate DNA from Sediment, Algorithm to Construct Signaling Networks

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Featured Webinar

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In PCR

  1. Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

  2. DiaSorin to Acquire Luminex for $1.8B

  3. OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence

    Premium

  4. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

    Premium

  5. Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.